Dr Harbottle: S/MAR vectors

Using non-viral S/MAR plasmid vectors to develop prophylactic gene therapy for Birt-Hogg-Dubé Syndrome

Dr Richard Harbottle leads one of the Myrovlytis Trust gene therapy projects to develop a non-viral vector therapy for BHD. Building from their previous work, the Harbottle group are developing non-viral vectors which contain the Folliculin gene as a potential therapy for BHD syndrome.  The goal is to deliver these vector to the kidney, skin, or lung cells of BHD patients to overcome the symptoms caused by the mutated Folliculin gene.

Dr Harbottle is head of the Gene Therapy Research Group at Imperial College and Research Fellow at the National Heart and Lung Institute.

Find out more about Dr Harbottle and his lab:

If you would like to support this project, please donate here.